Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
OncoImmune
Biotech
2 cancer biotechs merge, creating global footprint
OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger.
Gabrielle Masson
Sep 25, 2024 10:54am
Merck takes $170M charge on abandoned COVID-19 drug
May 6, 2021 9:00am
Merck cans one COVID-19 drug, scraps a clinical trial of another
Apr 15, 2021 8:20am
Merck has better luck with 2nd COVID-19 drug attempt
Mar 8, 2021 7:10am
Merck must do a new trial for faltering $425M COVID-19 drug
Mar 3, 2021 7:55am
FDA tells Merck to show more data for its COVID-19 drug
Feb 26, 2021 3:55am
